References for EXJADE.com

References

Use this alphabetized list of all articles referred to in this Web site. Clicking on any title will bring you to the abstract.

About myelodysplastic syndromes. Aplastic Anemia and MDS International Foundation. http://www.aamds.org/aplastic/disease_information/myelodysplastic_synd/index.php. Updated May, 2010. Accessed October 5, 2010.
Aduloju SO, Palmer S, Eckman JR. Mortality in sickle cell patient transitioning from pediatric to adult program: 10 years Grady Comprehensive Sickle Cell Center experience [American Society of Hematology 50th Annual Meeting abstract 1426]. Blood. 2008;112(11):Abstract 1426.
Altes A, Remacha AF, Sarda P, et al. Early clinical impact of iron overload in stem cell transplantation. A prospective study. Ann Hematol. 2007;86(6):443-447.
American Society of Hematology Image Bank. www.ashimagebank.org. Accessed October 11, 2010.
Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23):2171-2179.
Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999;341(26):1986-1995.
Andrews NC. Forging a field: the golden age of iron biology [review]. Blood. 2008;112(2):219-230.
Angelucci E, Muretto P, Nicolucci A, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood. 2002;100(1):17-21.
Armand P, Kim HT, Cutler CS, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007;109(10):4586-4588.

LEARN MORE ABOUT
OPTIMIZING EXJADE
DOSING.

Use the Dosing
Simulator.

EXJADE FAQ

Find answers to all of
your EXJADE questions.

Learn more

Ballas SK. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol. 2001;38(1):30-36.
Bennett JM. Consensus statement on iron overload in myelodysplastic syndromes [Critical Review]. Am J Hematol. 2008;83:858-861.
Bennett JM; for the MDS Foundation's Working Group on Transfusion Iron Overload. Consensus statement on rion overload in myleodysplastic syndromes. Am J Hematol. 2008;83(11);858-861.
Beutler E, Victor Hoffbrand AV, Cook JD. Iron deficiency and overload [Am Soc Hematol Educ Program]. Hematology. 2003:40-61.
Cabantchik, Z, Breur W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol. 2005;18(2):277-287.
Cao A. Quality of life and survival of patients with β-thalassemia major [Editorial, Comments, and Views]. Haematologica. 2004;89(10):1157-1159.
Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther. 2007;29(5):909-917.
Cappellini MD, Cohen A, Eleftherlou A, Piga A, Porter J, Taher A. Guidelines for the Clinical Management of Thalassaemia. 2nd ed. Thalassaemia International Foundation; 2008.
Cappellini MD, Elalfy MS, Kattamis A, Seymour JF, Lee CL, Porter JB. Efficacy and safety of once-daily, oral iron chelator deferasirox (EXJADE^®) in a large group of regularly transfused patients with β-thalassemia major. Blood (American Society of Hematology Meeting Abstracts) 2008;112: Abstract 3878.
Cappellini MD, Porter J, El-Beshlawy A, Li C-K, Seymour JF, Elalfy M, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010;95(4): 557-566.
Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010;95(4):557-566.
Centers for Disease Control and Prevention. Hemochromatosis for Health Care Professionals Training Course Module. Department of Health and Human Services for Disease Control and Prevention (CDC) Website. http://www.cdc.gov/NCBDDD/hemochromatosis/training/index.html. Updated September 23, 2010. Accessed October 4, 2010.
Classification of myelodysplastic syndromes. National Cancer Institute. http://www.cancer.gov/cancertopics/pdq/treatment/myelodysplastic/HealthProfessional/page2. Updated March 19, 2010. Accessed October 12, 2010.
Dabari D, Kple-Faget P, Kwagyan J, et al. Circumstances of death in adult sickle cell disease patients. Am J Hematol. 2006; 81(11):858-863.
Data on file. Novartis Pharma AG, Basel, Switzerland.
Dayyani F, Conley AP, Strom SS, et al. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer. 116(9):2174-2179.
Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion. 2007;47(10):1919-1929.
Delea TE, Sofrygin O, Thomas SK, et al. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective. Pharmacoeconomics. 2007;25(4):329-342.
Desferal^® Summary of Product Characteristics. United Kingdom; Novartis Pharma 2010.
Desferal^® prescribing information. Steine, Switzerland: Novartis Pharma Stein AG; 2007
Dick M, Anie K, Darbyshire P, et al. Sickle Cell Disease in Childhood: Standards and Guidelines for Clinical Care. Detailed Guidance. 1st ed. NHS Sickle Cell and Thalassaemia Screening Programme in partnership with the Sickle Cell Society; 2006.
Donovan A, Andrews NC. The molecular regulation of iron metabolism [review]. Hematol J. 2004;5(5):373-380.
EXJADE^® summary of product characteristics. West Sussex, United Kingdom: Novartis Europharm Limited; 2011.
Gabutti V, Piga A. Results of long-term iron-chelating therapy [review]. Acta Haematol. 1996;95(1):26-36.
Gattermann N, Finelli C, Della Porta M, et al. Deferasirox in iron overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large1-year EPIC study. Leuk Res. 2010;34(9):1143-1150.
Gattermann N. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int J Hematol. 2008;88:24-29.
Gattermann N, Porter J, Lopes LF, Seymour J. Consensus statement on iron overload in myelodysplastic syndromes. Hematol Oncol Clin North Am. 2005;19(suppl 1):18-25.
General information about myelodysplastic syndromes. National Cancer Institute. http://www.cancer.gov/cancertopics/pdq/treatment/myelodysplastic/HealthProfessional. Updated March 19, 2010. Accessed October 5, 2010.
Giagounidis A. Improving treatment outcomes by understanding cytogenetics in myelodysplastic syndrome. Haematologica Reports. 2006;2(14):5-10
Goldberg SL. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes. Leuk Res. 2007;31(suppl 3):S16-S22.
Goldberg SL, Chen E, Corral M, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010;28(17):2847-2852.
Greenberg PL. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2002:136-161.
Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood.1997;89(6):2079-2088.
Greenberg PL, Kollerb CA, Cabantchik ZI, et al. Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. Leuk Res. 2010;34(12):1560-1565.
Greenberg PL, Koller CA, Glynos T, Paley C, Schiffer CA. Change in liver iron concentration, serum ferritin and labile plasma iron over 1 year of deferasirox (EXJADE^®) therapy in a cohort of patients with MDS. Greenberg PL et al. Poster presented at 10th International Symposium on Myelodysplastic Syndromes. [P104] Leuk Res. 2009;33 (suppl 1):S120.
Hasle H, Baumann I, Bergstrasser E, et al. The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Leukemia. 2004;18(12):2008-2014.
Hoffman R, Benz E, Shattil S, et al. Hematology: Basic Principles and Practice. 4th ed. Philadelphia, PA: Elsevier; 2005.
Jabbour E, Carcia-Manero G, Taher A, Kantarjian H. Managing iron overload in patients with myelodysplastic syndrome with oral deferasirox therapy. Oncologist. 2009;14:489-496.
Jastaniah W, Harmatz P, Pakbaz Z, et al. Transfusional iron burden and liver toxicity after bone marrow transplantation for acute myelogenous leukemia and hemoglobinopathies. Pediatr Blood Cancer. 2008;50(2):319-324.
Kattamis A, El-Beshlawy A, Seymour JF, et al. Efficacy, efficiency, and safety of deferasirox for treating transfusional iron overload in non-actively transfused patients [14th Congress of the European Hematology Association, abstract 1289]. In: Haematologica. 2009; 94[suppl.2]:513. Abstract 1289.
Kattamis C, Meddeb B, Ressayre-Djaffer C, Balakina TA. Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (EXJADE, ICL760) clinical trial programme. Poster presented at: 11th Congress of the European Hematology Association; June 15-18, 2006. Amsterdam, The Netherlands.
Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009; 120: 1961-1968.
Kutler D, Singh B, Satagopan J, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood. 2003;101(4):1249-1256.
Kushner JP, Porter JP, Olivieri NF. Secondary iron overload [Am Soc Hematol Educ Program]. Hematology. 2001:47-61.
Lee JW, Yoon SS, Shen ZX, et al. Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood. 2010;116(14):2448-2454.
Leong WI, Lönnerdal B. Hepcidin, the recently identified peptide that appears to regulate iron absorption [Recent advances in nutritional sciences]. J Nutr. 2004;134(1):1-4.
List AF, Baer MR, Steensma D, et al. Iron chelation with deferasirox (EXJADE^®) improves iron burden in patients with myelodysplastic syndromes (MDS). Poster presented at: American Society of Hematology 50th Annual Meeting. Blood. 2008;112(11): Abstract 634.
Locasciulli A, Oneto R, Bacigalupo A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation. Haematologica. 2007;92(1):11-8.
Maertens J, Demuynck H, Verbeken EK, et al. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant. 1999;24(3):307-312.
Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica. 2006;91(12): 1588-1590.
Malcovati L, Della Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myleodysplastic syndromes classified according to WHO criteria; a basis for clinical descision making. J Clin Oncol. 2005;23(3);7594-7603.
Malcovati L, Porta MGD, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23:7594-7603.
Marsh JC, Ball SE, Darbyshire P, Gordon-Smith EC. Guidelines for the diagnosis and management of acquired aplastic anaemia.
Br J Haematol. 2003;123(5):782-801.
Myelofibrosis. Merck Manual Home Edition. 2nd Home Edition, Online Version. http://www.merck.com/mmhe/sec14/ch178/ch178c.html. Updated October 2009. Accessed October 11, 2010.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. v.1.2009.
National Heart, Lung, and Blood Institute. The Management of Sickle Cell Disease. 4th ed. Bethesda, MD: National Institutes of Health; 2002. NIH publication 02-2117.
NHS Sickle Cell and Thalassaemia Screening Programme. Sickle Cell Disease in Childhood: Detailed guidance, standards and guidelines for clinical care. October 2006. http://sct.screening.nhs.uk/getdata.php?id=10763. Accessed August 16, 2010.
Olivieri NF. Progression of iron overload in sickle cell disease. Semin Hematol. 2001;38(1 suppl 1):57-62.
Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89(3):739-761.
Olivieri NF, Nathan DG, MacMillan JH. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331(9):574-578.
Patton N, Brown G, Leung M, Bavishi K, Taylor J, Lloyd J, et al. Observational study of iron overload as assessed by magnetic resonance imaging in an adult population of transfusion dependent patients with beta thalassaemia: significant association between low cardiac T2* < 10 ms and cardiac events. Internal Med J. 2010;40(6):419-426.
Payne KA, Desrosiers MP, Caro JJ, et al. Clinical and economic burden of infused iron chelation therapy in the United States. Transfusion. 2007;47(10):1820-1829.
Pennell DJ, Porter JB, Cappellini MD, et al. Continued improvement and normalization of myocardial T2* in patients with β-thalassemia major treated with deferasirox (EXJADE^®) for up to 3 Years. Abstract presented at: 52nd Annual Meeting of the American Society of Hematology; December 2010; Orlando, Florida.
Pennell D, Porter JB, Cappellini MD, et al. Continued improvement in cardiac T2* with deferasirox treatment over 2 years: results from the extension of EPIC cardiac substudy in beta-thalassaemia patients with myocardial siderosis. Poster presented at: 15th Congress of the European Hematology Association; June 10-13, 2010; Barcelona, Spain.
Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy and safety of deferasirox (EXJADE^®) in β-thalassemia patients with myocardial siderosis: 2-year results from the EPIC cardiac sub-study. Poster presented at: 51st annual American Society of Hematology Meeting; December 5-8, 2009; New Orleans, LA.
Pennell D, Porter JB, Cappellini MD, et al. Efficacy and safety of deferasirox (EXJADE^®) in reducing cardiac iron in patients with β-thalassemia major: results from the cardiac substudy of the EPIC trial. Poster presented at: 50th American Society of Hematology Annual Meeting and Exposition; December 6-9, 2008; San Francisco, CA. Abstract 3873.
Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia. Blood. 2010;115(12):2364-2371.
Pennell DJ, Porter JB, Cappellini MD, El-Beshlawy A, Lee CL, Aydinok Y, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia. Blood. 2010;115(12):2364-2371.
Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, et al. Efficacy and safety of deferasirox (Exjade^®) in β-thalassemia patients with myocardial siderosis: 2-year results from the EPIC cardiac sub-study. Poster presented at: 51st annual American Society of Hematology Meeting; December 5-8, 2009; New Orleans, LA.
Pennell DJ, Porter JB, Cappellini MD, et al. Continued improvement and normalization of myocardial T2* in patients with β-thalassemia major treated with deferasirox (EXJADE^®) for up to 3 years. Poster presented at: 52nd Annual Meeting of the American Society of Hematology; December 2010; Orlando, Florida.
Piga A, Vichinsky E, Forni GL, Kilinc Y, Maseruka H, Kattamis A. Long-term efficacy and safety with deferasirox (EXJADE, ICL670), a once-daily oral iron chelator, in pediatric patients. Blood. 2007;110(11): Abstract 2774.
Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80(2):168-176.
Porter JB. Pathophysiology of iron overload. Hematol Oncol Clin North Am. 2005;19 (suppl 1):7�12.
Porter JB. Practical management of iron overload. Br J Haematol. 2001; 115(2):239-252.
Porter JB, Cappellini MD, El-Beshlawy A, et al. Effect of deferasirox (EXJADE^®) on labile plasma iron levels in heavily iron-overloaded patients with transfusion-dependent anemias enrolled in the large- scale, prospective 1-Year EPIC trial [American Society of Hematology 50^th Annual Meeting]. In: Blood. 2008;12: Abstract 3881.
Porter JB, Davis BA. Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. Best Pract Res Clin Haematol. 2002;15(2):329-368.
Porter JB, Lin KH, Habr D, et al. Efficacy and safety for the treatment of transfusion-dependent iron overload in patients with a range of rare anemias. [American Society of Hematology 50th Annual Meeting, abstract 640]. In: Blood. 2008;112(11): Abstract 1419.
Prevalence of rare diseases: Bibliographic data, Orphanet Report Series, Rare Diseases collection, May 2010,Number 1: Listed in alphabetical order of diseases.
Pullarkat V, Blanchard S, Tegtmeier B. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2008;42(12):799-805.
Roggero S, Quarello P, Vinciguerra T, et al. Severe iron overload in blackfan-diamond anemia: A case-control study. Am J Hematol. 2009;84(11):729-732.
Sakuta J, Ito Y, Kimura Y, Park J, Tokuuye K, Ohyashiki K. Appropriate evaluation of transfusional cardiac iron overload by T2* and R2* magnetic resonance [15^th Congress of the European Haematology Association, abstract 1837] Haematologica Abstract Book. Abstract 1837. 15^th Congress of the European Haematology Association Abstract Book.
Sanz G, Benet N, Such E, et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome [American Society of Hematology 50th Annual Meeting, abstract 640]. In: Blood. 2008;112(11): Abstract 640.
Sanz G, Nomdedeu B, Such E, et al. Slides presented at: American Society of Hematology 50th Annual Meeting; December 6-9, 2008; San Francisco, CA.
Standards for the Clinical Care of Adults with Sickle Cell Disease in the UK. Sickle Cell Society. 2008.
Taher T, Al Jefri A, Elalfy MS, Al Zir K, Daar S, Rofail D, et al. Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with β-thalassemia: results from the ESCALATOR trial. Acta Haematol. 2010;123(4):220-225.
Taher T, Cappellini MD, Vichinsky E, Galanello R, Piga A, Lawniczek T, et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol. 2009;147:752-759.
Takatoku M, Uchiyama T, Okamoto S, et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol. 2007;78(6):487-494.
Tchernia G, E. Vichinsky E, Jeng M, et al. The once-daily oral iron chelator ICL670 is well tolerated and effective in treating transfusional iron overload in diamond blackfan anemia patients. Abstract 0475. [The European Haematological Society 10th Annual Meeting]. Haematologica. 2005;90(suppl 2): Abstract 0475.
Vichinsky E. Clinical application of deferasirox: Practical patient management. Am J Hematol. 2008;83(5):398-402.
Vichinsky E, Coates T, Thompson AA, et al. Deferasirox (Exjade^®), the once-daily oral iron chelator, demonstrates safety and efficacy in patients with sickle cell disease (SCD): 3.5-year follow-up [American Society of Hematology 50th Annual Meeting abstract 1420]. Blood. 2008;112(11):Abstract 1420.
Vichinsky E. Consensus document for transfusion-related iron overload. Semin Hematol. 2001;38(1)(suppl 1):2-4.
Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136(3):501-508.
Vichinsky E, Pakbaz Z, Onyekwere O, et al. Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open label phase II trial. Acta Haematol. 2008;119(3):133-141.
Vlachos A, Ball S, Dahl N, et al. Diagnosing and treating diamond blackfan anaemia: results of an international clinical consensus conference. Br J Haematol. 2008;142(6):859-876.
Wood JC, Kang BP, Thompson A, Giardina P, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood. 2010;116 (4): 537-543.
World Health Organization. Sickle-Cell Anaemia. Fifty-Ninth World Health Assembly, Provisional Agenda Item 11.4.. Published April 2006. Accessed November 8, 2010.
Zanninelli G, Breurer W, Cabantchik ZI. Daily labile plasma iron as an indicator of chelator activity in thalassaemia major patients.
Br J Haematol. 2009;147(5):744-751.
Zurlo MG, De Stefano P, Di Palma A, et al. Survival and causes of death in thalassaemia major. Lancet. 1989;2(8653):27-30.

Welcome to the EXJADE Product Website

EXJADE is approved for use in 108 countries around the world.

EXJADE Country-Level Websites

EXJADE International Website

In this section:

References for EXJADE.com

References

LEARN MORE ABOUT
OPTIMIZING EXJADE
DOSING.

EXJADE FAQ

Welcome to the EXJADE Product Website

EXJADE is approved for use in 108 countries around the world.

EXJADE Country-Level Websites

EXJADE International Website

In this section:

References for EXJADE.com

References

LEARN MORE ABOUTOPTIMIZING EXJADEDOSING.

EXJADE FAQ

LEARN MORE ABOUT
OPTIMIZING EXJADE
DOSING.